Spots Global Cancer Trial Database for fibroblast growth factor receptor (fgfr)
Every month we try and update this database with for fibroblast growth factor receptor (fgfr) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC) | NCT03762122 | Squamous-cell N... | Rogaratinib | 18 Years - | Swiss Group for Clinical Cancer Research | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma | NCT01703481 | Tumor or Lympho... | JNJ-42756493: P... JNJ-42756493: P... JNJ-42756493: P... JNJ-42756493: P... | 18 Years - | Janssen Research & Development, LLC | |
| An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies | NCT03144661 | Hepatocellular ... Cholangiocarcin... Esophageal Canc... Nasopharyngeal ... Ovarian Cancer Solid Tumors | INCB062079 | 18 Years - | Incyte Corporation | |
| A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma | NCT02699606 | Neoplasm | Erdafitinib | 18 Years - | Janssen Research & Development, LLC | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma | NCT01703481 | Tumor or Lympho... | JNJ-42756493: P... JNJ-42756493: P... JNJ-42756493: P... JNJ-42756493: P... | 18 Years - | Janssen Research & Development, LLC | |
| An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies | NCT03144661 | Hepatocellular ... Cholangiocarcin... Esophageal Canc... Nasopharyngeal ... Ovarian Cancer Solid Tumors | INCB062079 | 18 Years - | Incyte Corporation | |
| NCCH2006/MK010 Trial (FORTUNE Trial) | NCT04962867 | Advanced or Rec... FGFR Gene Alter... | E7090 | 20 Years - | National Cancer Center, Japan | |
| Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration | NCT05253807 | Non-Small Cell ... | Pemigatinib | 18 Years - 99 Years | Incyte Corporation | |
| Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC) | NCT03762122 | Squamous-cell N... | Rogaratinib | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC) | NCT03762122 | Squamous-cell N... | Rogaratinib | 18 Years - | Swiss Group for Clinical Cancer Research |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
